Alimera Sciences Inc

Alimera Sciences — Technical Presentation (May 2011)

15 slides from Alimera Sciences's technical presentation, May 5, 2011

  1. Slide 1: Duration of DME Subgroup Analysis of the FAME Study

    Alimera Sciences, Inc. Duration of DME Subgroup Analysisof the FAME StudyWebcastMay 5, 2011 1

  2. Slide 2: Percentage of Patients With ≥15-Letter Improvement Over Baseline, FAME A+B

    Time (Months) Patients (%) P = .018 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME A+B, Full Population Primary Readout P = .002

  3. Slide 3: Subgroup

    Subgroup Ideal subgroup should meet the following: Statistically significant VA results at month 24 and 36 Greater benefit to risk ratio Identifiable prior to administration of ILUVIEN

  4. Slide 4: Baseline Demographics and Disease Characteristics, FAME A + B

    Baseline Demographics and Disease Characteristics, FAME A + B, DME ^ 3 Year Subgroup, Full Population FAME A + B, DME ^ 3 Year Subgroup, Full Population FAME A + B, DME ^ 3 Year Subgroup, Full Population

  5. Slide 5: FAME A Duration of DME Subgroup Analysis

    FAME A Duration of DME Subgroup Analysis

  6. Slide 6: .010 A, DME ^ = .004

    Time (Months) Patients (%) P = .010 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME A, DME ^ 3 Year Subgroup Primary Readout P = .004

  7. Slide 7: .441 A, DME < = .836

    Time (Months) Patients (%) P = .441 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME A, DME < 3 Year Subgroup Primary Readout P = .836

  8. Slide 8: FAME B Duration of DME Subgroup Analysis

    FAME B Duration of DME Subgroup Analysis

  9. Slide 9: .004 B, DME ^ = .006

    Time (Months) Patients (%) P = .004 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME B, DME ^ 3 Year Subgroup Primary Readout P = .006

  10. Slide 10: .424 B, DME < = .886

    Time (Months) Patients (%) P = .424 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME B, DME < 3 Year Subgroup Primary Readout P = .886

  11. Slide 11: FAME A + B Duration of DME Subgroup Analysis

    FAME A + B Duration of DME Subgroup Analysis

  12. Slide 12: < .001 A + B, DME ^ < .001

    Time (Months) Patients (%) P < .001 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME A + B, DME ^ 3 Year Subgroup Primary Readout P < .001

  13. Slide 13: .275 A + B, DME < = .984

    Time (Months) Patients (%) P = .275 Percentage of Patients With ^ 15-Letter Improvement Over Baseline, FAME A + B, DME < 3 Year Subgroup Primary Readout P = .984

  14. Slide 14: Safety Profile: Cataract-Related and IOP-Related Events

    Cataract-Related Events Cataract-Related Events DME ^ 3 Year Subgroup DME ^ 3 Year Subgroup Full Population Full Population Patients, %(Study Eye) Control(n = 112) 0.2 µg/d FAc (n = 209) Control(n = 112) 0.2 µg/d FAc (n = 209) IOP > 30 mm Hgb 5.4 14.8 4.3 18.4 Trabeculoplasty 0.0 1.9 0.0 1.3 Incisio

  15. Slide 15: Duration of DME Subgroup Analysis of the FAME Study

    Alimera Sciences, Inc. Duration of DME Subgroup Analysisof the FAME StudyWebcastMay 5, 2011 1

Alimera Sciences — Technical Presentation (May 2011) on 6ix